¹®¿ëÈ
Ç÷¾×Á¾¾ç³»°úÀå
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : À¯¹æ¾Ï, ºÎÀξÏ, Àü¸³¼±¾Ï
Á÷
ˤ
: ±³¼ö(Ç÷¾×Á¾¾ç³»°úÀå)
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
18
ÇØ¿Ü
Moon YW, Hajjar J, Hwu P, et al.. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 3:51, 2015
17
ÇØ¿Ü
Kim HS, Kim SM, Kim H, Pyo KH, Sun JM, Ahn MJ, Park K, Keam B, Kwon NJ, Yun HJ, Kim HG, Chung IJ, Lee JS, Lee KH, Kim DJ, Lee CG, Hur J, Chung H, Park JC, Shin SK, Lee SK, Kim HR, Moon YW, et al..Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. Oncotarget 6: 44971-84; 2015
16
ÇØ¿Ü
Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, Moon YW, et al..Anti-tumor activity and acquired resistance mechanism of Dovitinib (TKI258) in RET rearranged lung adenocarcinoma. Mol Cancer Ther. pii: molcanther.0350.2015 (epub)
15
ÇØ¿Ü
Park JS, Lee JS, Kim EY, Jung JY, Kim SK, Chang J, Kim DJ, Lee CY, Jung I, Kim JH, Kim HR, Moon YW, et al.. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lungcancer. Lung Cancer 88: 325-331, 2015
14
ÇØ¿Ü
Jung M, Koo JS, Moon YW, et al.. Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. PLoS One 7(9):e45127, 2012
13
ÇØ¿Ü
Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al.. The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. Ann Surg Oncol 17: 3259-3268, 2010
12
ÇØ¿Ü
Moon YW, Rha SY, Shin SJ, et al.. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 136:387-394, 2010
11
ÇØ¿Ü
Rha SY, Jeung HC, Seo MY, Kim SC, Yang WI, Moon YW, et al.. Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. Int J Oncol 34:837-846, 2009
10
ÇØ¿Ü
Jeung H-C, Moon YW, Rha SY, et al.. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol 19:520-526, 2008
9
ÇØ¿Ü
Moon YW*, Choi SH*, Kim YT, et al..Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based two-drug chemotherapy for unresectable non-small cell lung cancer. (*Both equally contributed). Cancer 109:1829-1835, 2007
1
2
3
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729